AURKA and Miyoshi myopathy: Because selinexor is clinically available for relapsed/refractory MM and as AURKA is overexpressed in malignancies, we hypothesized that dual inhibition of nuclear export and mitotic regulation could represent a rational therapeutic strategy for these aggressive disease subsets.